Yet, the clinical utility of established biomarkers is limited in particular by their lack of sensitivity for the early detection of HF. Metabolomics of plasma samples was performed by both untargeted and targeted GC-MS and LC-MS/MS. In the initial single center identification phase metabolites were nominated for multimarker panels and their performance was verified in an independent validation cohort from three clinical centers (in total >800 HF patients and >330 healthy controls). The metabolite multimarkers not only showed a similar diagnostic performance compared to NT-proBNP, but also demonstrated a significant added diagnostic value when combining with NT-proBNP for several HF subgroups. We conclude that metabolomic biomarkers may be useful in the early detection of HF.
New Metabolomics Biomarker for Heart Failure
Video Apr 27, 2015
For scientists whose research requires high-precision isotope ratio data in fields of cosmo- and geochemistry, geochronology and biology, nuclear safeguards, forensics, metalomics, and provenance studies, we have created a new multicollector ICP-MS. Designed and developed in Bremen, building on the strengths of our multi-collector platform with field-proven technologies such as RPQ, 10^13 ohm Amplifier Technology and Jet Interface.WATCH NOW
This instalment of Teach Me in 10 features Dr Lorna Nisbet, a senior lecturer at Anglia Ruskin University. Lorna’s research interests are within the field of forensic toxicology where she specializes in the detection of new psychoactive substances that have been chemically altered to produce new types of high.WATCH NOW